Clinical trials recruiting for Metastatic Solid Tumor

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
  NCT07172802 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  NCT07602842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of KK2269 in Adult Participants With Solid Tumors
  NCT06266299 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
  NCT05837767 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
  NCT06975410 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
  NCT07284186 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
  NCT04977453 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• High Definition Medicine for Solid Tumors Oncology
  NCT06590506 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 18 locations
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
  NCT06171750 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
  NCT05898399 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
  NCT06974110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT06666270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations

Related conditions

Trials recruiting for Metastatic Solid Tumor often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic Solid Tumor trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.